A Company Tried To Sue Over Palantir's Usage
Over the past month, c3ai has been the talk of the town, with its stock price soaring over a hundred percent. There has been a lot of buzz about the impact of AI on the world, with Google competing with Microsoft, and the likes of ChatGPT and other new entrants in the field. However, c3ai has been the recipient of much attention, with its stock price even surpassing Microsoft's. Why is this the case? Well, it could be because their ticker symbol is AI.
Yes, you read that right. c3ai is literally up because of its ticker symbol. It is not because of their earnings or their leadership, as their recent earnings were horrendous. The CEO of c3's AI even made controversial remarks about Facebook, which did not reflect well on the company's management. However, this article is not about that. It is about recent news that sheds some light on the company's reputation and business practices.
According to a recent article, the Centers for Disease Control and Prevention (CDC) has rejected a protest by c3ai against a task order requiring the use of Palantir software, which c3ai claims it was not an interested party. In December, Palantir received a contract worth $445 million over the next five years from the CDC to prevent public health outbreaks. The disputed task order, which was set aside for service-disabled veteran-owned small businesses and awarded to Virginia-based Information Technology reseller I3 Federal LLC, will support the CDC's common operating picture SAS solution.
The exact value of the task order is not specified in the decision, but it is above $25 million, according to a December 7 Palantir press release. The CDC will continue to bring several existing programs that use the company software into a single platform to plan, manage, and respond to future outbreaks. These are federal reselling software packages that Palantir partners with all the time.
C3ai, a California-based provider of AI and software platforms, claimed that the brand name justification used by the CDC to require the use of Palantir's Foundry was improper. The CDC alleged that the protest was untimely, as the agency had first issued a public notice that it intended to issue the procurement with recruitment for Palantir products in early September. C3ai did not protest until December, which passed the deadline for submitting protests.
The crux of the issue here is that c3ai is not touching Palantir, despite the buzz around AI and its impact on the world. While c3ai's stock price may be soaring because of its ticker symbol, it is not a real company that is making real business decisions. It is merely riding the momentum of Wall Street bets and social media hype. If it were a real company, it would prefer to be flat during this time or even down and have a real run when Wall Street gets it.
In conclusion, the rise of c3ai is a ticker symbol phenomenon that is not reflective of the company's reputation or business practices. The recent news about its protest against a Palantir task order sheds some light on the company's approach to business. It is clear that c3ai is not in the same league as real AI companies like Palantir, and its stock price is not a reflection of its true value. As with any investment, investors should do their due diligence and research before investing in c3ai or any other company.
Thanks for reading the article. If you'd like to get in contact, please @ me on twitter here or email me at firstname.lastname@example.org. You can join our Palantir Facebook group here to participate in community discussions, polls, and more. You can check out daily palantir audio content here.